Overview

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Status:
RECRUITING

Trial end date:
2028-03-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

bimekizumab